Regulation of programmed cell death by plasminogen activator inhibitor type 1 (PAI-1)

Thrombosis and Haemostasis

Volumn 100, Issue 6, 2008, Pages 1041-1046

  Lademann, Ulrik A ^a   Rømer, Maria Unni ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Apoptosis; Cancer; Normal cells; PAI 1

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; INTERLEUKIN 1; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; N METHYL DEXTRO ASPARTIC ACID; NERVE GROWTH FACTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL KINASE; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TENSIN; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UROKINASE; UROKINASE RECEPTOR; VERY LOW DENSITY LIPOPROTEIN RECEPTOR; VITRONECTIN;

ANOIKIS; APOPTOSIS; CANCER CELL; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL SURVIVAL; ENDOTHELIUM CELL; ENZYME REGULATION; EXTRACELLULAR MATRIX; HUMAN; METABOLIC REGULATION; PATHOPHYSIOLOGY; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

ANIMALS; APOPTOSIS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 57349164242     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-04-0266     Document Type: Review

References (75)

1. Beyer BCM, Heiss MM, Simon EH, et al. Urokinase system expression in gastric carcinoma - Prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens. Cancer 2006; 106: 1026-1035.
2. Grondahl H, Christensen IJ, Rosenquist C, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993; 53: 2513-2521.
3. Hofmann R, Lehmer A, Buresch M, et al. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer 1996; 78: 487-492.
4. Pedersen H, Brunner N, Francis D, et al. Prognostic impact of urokinase, urokinase receptor, and type-1 plasminogen-activator inhibitor in squamous and large-cell lung-cancer tissue. Cancer Res 1994; 54: 4671-4675.
5. Stahl A, Mueller BM. Melanoma cell migration on vitronectin: Regulation by components of the plasminogen activation system. Int J Cancer 1997; 71: 116-122.
6. Bajou K, Noel A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nature Med 1998; 4: 923-928.
7. Gutierrez LS, Schulman A, Brito-Robinson T, et al.. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 2000; 60: 5839-5847.
8. Maillard C, Jost M, Romer MU, et al. Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner. Neoplasia 2005; 7: 57-66.
9. Palmieri D, Lee JW, Juliano RL, Church FC. Plasminogen Activator Inhibitor-1 and -3 Increase Cell Adhesion and Motility of MDA-MB-435 Breast Cancer Cells. J Biol Chem 2002; 277: 40950-40957.
10. Andreasen PA. PAI-1 - a potential therapeutic target in cancer. Curr Drug Targets 2007; 8: 1030-1041.
11. Cao C, Lawrence DA, Li Y, et al. Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration. EMBO J 2006; 25: 1860-1870.
12. Huntington JA, Read RJ, Carrell RW. Structure of a serpin-protease complex shows inhibition by deformation. Nature 2000; 407: 923-926.
13. Cubellis MV, Wun TC, Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 1990; 9: 1079-1085.
14. Nykjaer A, Conese M, Christensen EI, et al. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J 1997; 16: 2610-2620.
15. Heegaard CW, Simonsen AC, Oka K, et al. Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex. J Biol Chem 1995; 270: 20855-20861.
16. Stefansson S, Muhammad S, Cheng XF, et al. Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein. J Biol Chem 1998; 273: 6358-6366.
17. Skeldal S, Larsen JV, Pedersen KE, et al. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis. FEBS J 2006; 273: 5143-5159.
18. Webb DJ, Thomas KS, Gonias SL. Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth. J Cell Biol 2001; 152: 741-752.
19. Campana WM, Li X, Dragojlovic N, et al. The low-density lipoprotein receptor-related protein is a pro-survival receptor in Schwann cells: possible implications in peripheral nerve injury. J Neurosci 2006; 26: 11197-1207.
20. Montel V, Gaultier A, Lester RD, et al. The low-density lipoprotein receptor-related protein regulates cancer cell survival and metastasis development. Cancer Res 2007; 67: 9817-9824.
21. Germer M, Kanse SM, Kirkegaard T, et al. Kinetic analysis of integrin-dependent cell adhesion on vitronectin - the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides. Eur J Biochem 1998; 253: 669-674.
22. Seiffert D, Smith JW. The cell adhesion domain in plasma vitronectin is cryptic. J Biol Chem 1997; 272: 13705-13710.
23. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 1996; 383: 441-443.
24. Lazar MH, Christensen PJ, Du M, et al. Plasminogen Activator Inhibitor-1 Impairs Alveolar Epithelial Repair by Binding to Vitronectin. Am J Respir Cell Mol Biol 2004; 31: 672-678.
25. Deng G, Curriden SA, Hu G, et al. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J Cell Physiol 2001; 189: 23-33.
26. Schar CR, Blouse GE, Minor KH, et al. A deletion mutant of vitronectin lacking the somatomedin B domain exhibits residual plasminogen activator inhibitor-1-binding activity. J Biol Chem 2008; 283: 10297-10309.
27. Schar CR, Jensen JK, Christensen A, et al. Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain. J Biol Chem 2008; 283: 28487-28496.
28. Chen SC, Henry DO, Reczek PR, et al. Plasminogen activator inhibitor-1 inhibits prostate tumor growth through endothelial apoptosis. Mol Cancer Ther 2008; 7: 1227-1236.
29. Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. Cell 1997; 88: 347-354.
30. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-1462.
31. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-776.
32. Krammer PH. CD95's deadly mission in the immune system. Nature 2000; 407: 789-795.
33. Nicholson DW. From bench to clinic with apoptosis-based therapeutic agents. Nature 2000; 407: 810-816.
34. Jaattela M. Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene 2004; 23: 2746-2756.
35. Jaattela M. Escaping cell death: survival proteins in cancer. Exp Cell Res 1999; 248: 30-43.
36. Boudreau N, Sympson CJ, Werb Z, et al. Suppression of ICE and apoptosis in mammary epithelial cells by extra-cellular matrix. Science 1995; 267: 891-893.
37. Raff MC, Barres BA, Burne JF, et al. Programmed Cell-Death and the Control of Cell-Survival - Lessons from the Nervous-System. Science 1993; 262: 695-700.
38. Cheng GZ, Park S, Shu SK, et al. Advances of AKT pathway in human oncogenesis and as a target for anticancer drug discovery. Current Cancer Drug Targets 2008; 8: 2-6.
39. Henson ES, Gibson SB. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: Implications for cancer therapy. Cell Signalling 2006; 18: 2089-2097.
40. Li HC, Fan XL, Houghton J. Tumor microenvironment: The role of the tumor stroma in cancer. J Cell Biochem 2007; 101: 805-815.
41. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411: 375-379.
42. Usher PA, Thomsen OF, Iversen P, et al. Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. Int J Cancer 2005; 113: 870-880.
43. Offersen BV, Nielsen BS, Hoyer-Hansen G, et al. The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas. Am J Pathol 2003; 163: 1887-1899.
44. Illemann M, Hansen U, Nielsen HJ, et al. Leading-edge myofibroblasts in human colon cancer express plasminogen activator inhibitor-1. Am J Clin Pathol 2004; 122: 256-265.
45. Lindberg P, Larsson A, Nielsen BS. Expression of plasminogen activator inhibitor-1, urokinase receptor and laminin gamma-2 chain is an early coordinated event in incipient oral squamous cell carcinoma. Int J Cancer 2006; 118: 2948-2956.
46. Hundsdorfer B, Zeilhofer HF, Bock KP, et al. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value. J Cranio-Maxillofacial Surg 2005; 33: 191-196.
47. Providence K, Higgins S, Mullen A, et al. SERPINE1 (PAI-1) is deposited into keratinocyte migration "trails" and required for optimal monolayer wound repair. Arch Dermatol Res 2008; 300: 303-310.
48. Kwaan HC, Wang J, Svoboda K, et al. Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br J Cancer 2000; 82: 1702-1708.
49. Kimura M, Soeda S, Oda M, et al. Release of plasminogen activator inhibitor-1 from human astrocytes is regulated by intracellular ceramide. J Neurosci Res 2000; 62: 781-788.
50. Soeda S, Shinomiya K, Ochiai T, et al. Plasminogen activator inhibitor-1 aids nerve growth factor-induced differentiation and survival of pheochromocytoma cells by activating both the extra-cellular signal-regulated kinase and c-Jun pathways. Neuroscience 2006; 141: 101-108.
51. Soeda S, Oda M, Ochiai T, et al. Deficient release of plasminogen activator inhibitor-1 from astrocytes triggers apoptosis in neuronal cells. Mol Brain Res 2001; 91: 96-103.
52. Gill JS, Schenone AE, Podratz JL, et al. Autocrine regulation of neurite outgrowth from PC12 cells by nerve growth factor. Mol Brain Res 1998; 57: 123-131.
53. Greene LA, Tischler AS. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth-factor. Proceedings of the National Academy of Sciences of the United States of America 1976; 73: 2424-2428.
54. Zielke A, Bresalier RS, Siperstein AE, et al. A unique allogenic model of metastatic pheochromocytoma: PC12 rat pheochromocytoma xenografts to nude mice and establishment of metastases-derived PC12 variants. Clin Exp Metastasis 1998; 16: 341-352.
55. Lademann U, Romer MU, Jensen PB, et al. Malignant transformation of wild-type but not plasminogen activator inhibitor-1 gene-deficient fibroblasts decreases cellular sensitivity to chemotherapy-mediated apoptosis. Eur J Cancer 2005; 417: 1095-100.
56. Romer MU, Kirkebjerg DA, Knud LJ, et al. Indication of a role of plasminogen activator inhibitor type I in protecting murine fibrosarcoma cells against apoptosis. Thromb Haemost 2005; 94: 859-866.
57. Romer MU, Larsen L, Offenberg H, et al. Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposide-induced apoptosis through activation of the PI3K/Akt cell survival pathway. Neoplasia 2008; 10: 1083-1091.
58. Han BH, Holtzman DM. BDNF protects the neonatal brain from hypoxic-ischemic injury in vivo via the ERK pathway. J Neurosci 2000; 20: 5775-5781.
59. Buisson A, Nicole O, Docagne F, et al. Up-regulation of a serine protease inhibitor in astrocytes mediates the neuroprotective activity of transforming growth factor beta 1. Faseb J 1998; 12: 1683-1691.
60. Gabriel C, Ali C, Lesne S, et al. Transforming growth factor alpha-induced expression of type-1 plasminogen activator inhibitor in astrocytes rescues neurons from excitotoxicity. Faseb J 2003; 16: 277-279.
61. Thornton P, Pinteaux E, Allan SM, et al. Matrix metalloproteinase-9 and urokinase plasminogen activator mediate interleukin-1-induced neurotoxicity. Mol Cell Neurosci 2008; 37: 135-142.
62. Rossignol P, Luttun A, Martin-Ventura JL, et al. Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques. J Thromb Haemost 2006; 4: 664-670.
63. Rossignol P, Angles-Canos E, Lijnen HR. Plasminogen activator inhibitor-I impairs plasminogen activation-mediated vascular smooth muscle cell apoptosis. Thromb Haemost 2006; 96: 665-670.
64. Horowitz JC, Rogers DS, Simon RH, et al. Plasminogen activation-induced pericellular fibronectin proteolysis promotes fibroblast apoptosis. Am J Respir Cell Mol Biol 2008; 38: 78-87.
65. Al-Fakhri N, Chavakis T, Schmidt-Woll T, et al. Induction of apoptosis in vascular cells by plasminogen activator inhibitor-1 and high molecular weight kininogen correlates with their anti-adhesive properties. Biol Chem 2003; 384: 423-435.
66. Chen YB, Kelm RJ, Budd RC, et al. Inhibition of apoptosis and caspase-3 in vascular smooth muscle cells by plasminogen activator inhibitor type-1. J Cell Biochem 2004; 92: 178-188.
67. Das F, Ghosh-Choudhury N, Venkatesan B, et al. Akt kinase targets association of CBP with SMAD 3 to regulate TGF beta-induced expression of plasminogen activator inhibitor-1. J Cell Physiol 2008; 214: 513-527.
68. Kietzmann T, Jungermann K, Gorlach A. Regulation of the hypoxia-dependent plasminogen activator inhibitor I expression by MAP kinases. Thromb Haemost 2003; 89: 666-673.
69. Mukai Y, Wang CY, Rikitake Y, Liao JK. Phosphatidylinositol 3-kinase/protein kinase Akt negatively regulates plasminogen activator inhibitor type 1 expression in vascular endothelial cells. Am J Physiol-Heart Circul Physiol 2007; 292: H1937-H1942.
70. Whitley BR, Beaulieu LM, Carter JC, et al. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells. Gynecol Oncol 2007; 104: 470-479.
71. Balsara RD, Castellino FJ, Ploplis VA. A novel function of plasminogen activator inhibitor-1 in modulation of the AKT pathway in wild-type and plasminogen activator inhibitor-1-deficient endothelial cells. J Biol Chem 2006; 281: 22527-22536.
72. Kortlever RM, Higgins PJ, Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nature Cell Biol 2006; 8: 877-U155.
73. Alfano D, Iaccarino I, Stoppelli MP. Urokinase signaling through its receptor protects against anoikis by increasing BCL-xL expression levels. J Biol Chem 2006; 281: 17758-17767.
74. Jensen JK, Durand MK, Skeldal S, et al. Construction of a plasminogen activator inhibitor-1 variant without measurable affinity to vitronectin but otherwise normal. FEBS Lett 2004; 556: 175-179.
75. Xu Z, Balsara RD, Gorlatova NV, et al. Conservation of critical functional domains in murine plasminogen activator inhibitor-1. J Biol Chem 2004; 279: 17914-17920.